SCHEMBL1018167

SCHEMBL1018167

Nc1ccnc(-c2ccncc2)n1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.47
ADORA2B P29275 1/20 0.44
HSP90AA1 P07900 1/20 0.43
L3MBTL1 Q9Y468 2/20 0.42
RXFP1 Q9HBX9 1/20 0.42
MAPT P10636 5/20 0.42
LMNA P02545 3/20 0.42
GABRA1 P14867 1/20 0.41
GABRG2 P18507 1/20 0.41
GABRB3 P28472 1/20 0.41
GABRA5 P31644 1/20 0.41
GABRA3 P34903 1/20 0.41
POLB P06746 2/20 0.41
SCN9A Q15858 1/20 0.40
CYP19A1 P11511 2/20 0.39
ALDH1A1 P00352 2/20 0.39
CYP2D6 P10635 2/20 0.39
KMT2A Q03164 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
MEN1 O00255 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL11514438 0.98 NPC1 (0.46) NPC1ADORA2BHSP90AA1L3MBTL1RXFP1
SCHEMBL1828161 0.83 ADORA2A (0.53) NPC1ADORA2BHSP90AA1L3MBTL1MAPT
SCHEMBL12443811 0.83 MEN1 (0.48) NPC1MAPTLMNACYP19A1ALDH1A1
SCHEMBL27754726 0.81 HSP90AA1 (0.42) HSP90AA1GABRA1GABRG2GABRB3GABRA5
SCHEMBL30462066 0.79 HSP90AA1 (0.40) ADORA2BHSP90AA1LMNAPOLBALDH1A1
SCHEMBL13662705 0.79 MEN1 (0.56) NPC1POLBSCN9AKMT2ASMN1; SMN2
SCHEMBL20390512 0.79 MEN1 (0.56) NPC1MAPTCYP19A1KMT2ASMN1; SMN2
SCHEMBL6826360 0.79 KMT2A (0.56) NPC1L3MBTL1MAPTLMNASCN9A
SCHEMBL30128655 0.79 MAPT (0.56) NPC1L3MBTL1RXFP1MAPTSCN9A
SCHEMBL3794168 0.79 TRPV3 (0.48) SCN9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114621222-B 6-6 Fused bicyclic heteroaryl compounds and their use as LATS inhibitors 诺华股份有限公司 2024-12-17 CN claimed
EP-2763982-B1 SUBSTITUTED BENZYLINDAZOLES FOR USE AS BUB1 KINASE INHIBITORS IN THE TREATMENT OF HYPERPROLIFERATIVE DISEASES. Bayer Pharma AG (DE) 2018-01-10 EP claimed
US-9416125-B2 2016-08-16 US claimed
EP-2976335-A1 HETEROARYL SUBSTITUTED INDAZOLES Bayer Pharma Aktiengesellschaft (DE) 2016-01-27 EP claimed
WO-2014147204-A1 HETEROARYL SUBSTITUTED INDAZOLES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2014-09-25 WO claimed
US-RE30024-E ANTIALLERGENS STERLING DRUG INC. (US) 1979-06-05 US claimed
US-4032523-A ANTIALLERGENS STERLING DRUG INC. (US) 1977-06-28 US claimed
US-20250197375-A1 PYRIMIDINES AND METHODS OF THEIR USE Kineta, Inc. 2025-06-19 US disclosed
CN-114621222-B 6-6 Fused bicyclic heteroaryl compounds and their use as LATS inhibitors 诺华股份有限公司 2024-12-17 CN disclosed
EP-4444309-A1 PYRIMIDINES AND METHODS OF THEIR USE Kineta, Inc. (US) 2024-10-16 EP disclosed
WO-2023107603-A1 PYRIMIDINES AND METHODS OF THEIR USE Kineta, Inc. (US) 2023-06-15 WO disclosed
EP-3301097-B1 [1]BENZOTHIENO[3',2':4,5]IMIDAZO[1,2-A]PYRIDINE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN ORGANIC LIGHT-EMITTING DEVICES (OLEDS) SAMSUNG DISPLAY CO LTD (KR) 2020-08-19 EP disclosed
EP-3693372-A1 BENZOFURO[3',2':4,5]IMIDAZO[1,2-A]PYRIDINE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN ORGANIC LIGHT-EMITTING DEVICES (OLEDS) Samsung Display Co., Ltd. (KR) 2020-08-12 EP disclosed
US-4109092-A FROM PYRIDINYL-CARBOXAMIDINE AND ALPHA-CHLOROACRYLONITRILE STERLING DRUG INC. (US) 1978-08-22 US disclosed
US-4086233-A ANTIALLERGENS STERLING DRUG INC. (US) 1978-04-25 US disclosed
US-4053475-A ANTI-ALLERGIC AGENTS STERLING DRUG INC. (US) 1977-10-11 US disclosed
US-4032523-A ANTIALLERGENS STERLING DRUG INC. (US) 1977-06-28 US disclosed
US-4018770-A ANTIALLERGENS STERLING DRUG INC. (US) 1977-04-19 US disclosed
US-4008235-A ANTIALLERGIC STERLING DRUG INC. (US) 1977-02-15 US disclosed
US-3992380-A 5,8-Dihydro-5-oxo-2-(4-or 3-pyridinyl)pyrido[2,3-d]pyrimidine-6-carboxylic acids and esters STERLING DRUG INC. (US) 1976-11-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250197375-A1 PYRIMIDINES AND METHODS OF THEIR USE TDP1, TYMP, TARDBP NPC1 768/4885ADORA2B 987/4885HSP90AA1 1651/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.